Center for Scientific Review; Notice of Closed Meetings, 46896-46897 [2024-11853]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
46896
Federal Register / Vol. 89, No. 105 / Thursday, May 30, 2024 / Notices
heavy metal. These changes can be
observed in patients in real time with a
specialized MRI approach called
hyperpolarization. By transiently
changing the nuclear spin of naturally
occurring intermediates in cellular
energy production, the metabolic fate
can be observed with greater than
10,000-fold sensitivity. Current methods
of hyperpolarization require expensive
machines with limited throughput.
Potential Commercial Applications:
• MRI imaging
• Hyperpolarization
• Infusion Device for imaging reagents
• Cancer diagnostics
• Cardiovascular disease diagnostics
Development Stage:
• Early stage
Inventors: Rolf E. Swenson (NHLBI),
Jessica H. Ettedgui-Benjamini (NHLBI),
Carolyn Woodroofe Hitko (NCI), Murali
K. Cherukuri (NCI), and Natarajan Raju
(NHLBI).
Intellectual Properties:
• HHS Reference No. E–035–2022–0
‘‘Preparation Of Isotopically Labeled
Ketoglutarates And Methods Of
Hyperpolarization Through Signal
Amplification By Reversible Exchange
(SABRE)’’; U.S. Provisional Patent
Application No. 63/303,190 filed
January 26, 2022; Patent Cooperation
Treaty Application PCT/US2023/011640
filed January 26, 2023.
• HHS Reference No. E–036–2022
‘‘Sabre Catalysts Containing Fluorinated
Carbon Chains For Delivery Of MetalFree MRI Contrast Agents’’; U.S.
Provisional Patent Application 63/
328,545 filed April 7, 2022; Patent
Cooperation Treaty Application PCT/
US2023/017885 filed April 7, 2023, U.S.
Patent Application 18/410,773 filed
January 11, 2024, Applications also
pending in Japan, Canada, Israel, China,
and Europe.
• HHS Reference No. E–052–2022
‘‘Infusion device for the preparation and
delivery of MRI probes,’’ U.S.
Provisional Patent Application 63/
328,556 filed April 7, 2022, Patent
Cooperation Treaty Application PCT/
US2023/017895 filed April 7, 2023.
• HHS Reference No. E–069–2020
‘‘Real-time Monitoring Of In Vivo Free
Radical Scavengers Through
Hyperpolarized [1-13C] N-acetyl
Cysteine,’’ U.S. Provisional Patent
Application 62/961,855 filed January
16, 2020, Patent Cooperation Treaty
Application PCT/US2021/013634 filed
January 15, 2021, European Patent
Application 21741034.9 filed January
15, 2021, Israeli Patent Application
294365 filed January 15, 2021, European
Patent Application 17/793,083 filed
January 15, 2021.
VerDate Sep<11>2014
20:03 May 29, 2024
Jkt 262001
• HHS Reference No. E–070–2020
‘‘Isotopes Of Alpha Ketoglutarate And
Related Compounds For Hyperpolarized
MRI Imaging,’’ U.S. Provisional Patent
Application 62/962,473 filed January
17, 2020, Patent Cooperation Treaty
Application PCT/US2021/013658 filed
January 15, 2021, European Patent
Application 21741941.5 filed January
15, 2021, Israeli Patent Application
294464 filed January 15, 2021, U.S.
Patent Application 17/793,089 filed
January 15, 2021.
• HHS Reference No. E–039–2022
‘‘Temperature Cycling Method for
Hyperpolarization of Target Molecules
and Contrast Agents using
Parahydrogen,’’ US Provisional Patent
Application 63/203591 filed July 27,
2021. Patent Cooperation Treaty
Application PCT/US2022/074122 filed
July 26, 2022, U.S. Application 18/
291,681.
Publications:
• Perfluorinated Iridium catalyst for
signal amplification by reversible
exchange provides metal-free aqueous
hyperpolarized [1-13C]-Pyruvate. J.
Ettedgui, B. Blackman, N. Raju, S.
Kotler, E. Chekmenev, B. Goodson, H.
Merkle, C. Woodroofe, C. LeClair, K.
Murali, R. Swenson J. Am. Chem. Soc.
2024, 146, 946–953.
• Monitoring response to a clinically
relevant IDH inhibitor in glioma—
Hyperpolarized 13C magnetic resonance
spectroscopy approaches. D. Hong, Y.
Kim, C. Mushti, N. Minami, J. Wu, M.
K. Cherukuri, R. E. Swenson, D. B.
Vigneron, S. M. Ronen. Neuro-Oncology
Advances 2023, DOI: https://
academic.oup.com/noa/article/5/1/
vdad143/7337326.
• Catalyst-Free Aqueous
Hyperpolarized 13C-Pyruvate Obtained
by Re-Dissolution Signal Amplification
by Reversible Exchange A. B. Schmidt;
H. de Maissin; I. Adelabu; S. Nantogma;
J. Ettedgui; P. TomHon; B. M Goodson.;
T. Theis; E. Y. Chekmenev. ACS Sensors
2022, 7 (11), 3430–3439.
• Rapid 13C Hyperpolarization of the
TCA-Cycle Intermediate a-Ketoglutarate
via SABRE–SHEATH. I. Adelabu, Isaiah;
Ettedgui, Jessica; Joshi, Sameer;
Nantogma, Shiraz; Chowdhury, Md
Raduanul; McBride, Stephen; Theis,
Thomas; Sabbasani, Venkata;
Chandrasekhar, Mushti; Sail, Deepak;
Yamamoto, Kazutoshi; Swenson, Rolf;
Krishna, Murali; Goodson, Boyd;
Chekmenev, Eduard. Anal. Chem. 2022,
94, 13422–13431.
• Order-Unity 13C Nuclear
Polarization of [1-13C]Pyruvate in
Seconds and the Interplay of Water and
SABRE Enhancement. I. Adelabu, P.
TomHon, M. S. H. Kabir, S Nantogma,
M. Abdulmojeed, I. Mandzhieva, J.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Ettedgui, R. E. Swenson, M. C. Krishna,
T. Theis, B. M. Goodson, and E. Y.
Chekmenev. ChemPhysChem. 2022, 23,
131–136.
• Simple esterification of [1-13C]alpha-ketoglutarate enhances membrane
permeability and allows for noninvasive tracing of glutamate and
glutamine production. J. AbuSalim, K.
Yamamoto, N. Miura, B. Blackman, J.
Brender, C. Mushti, T. Seki, K.
Camphausen, R. Swenson, M. Krishna,
A. Kesarwala. ACS Chem. Biol. 2021,
16, 2144–2150. DOI: 10.1021/
acschembio.1c00561
• Synthesis of [1-13 C–5–12 C]-alphaketoglutarate enables non-invasive
detection of 2-hydroxyglutarate. N.
Miura, C. Mushti, D. Sail, J. E. Bingham,
K. Yamamoto, J. R. Brender, T. Seki, D.
I. AbuSalim, S. Matsumoto, K. A.
Camphausen, M. C. Krishna, R. E.
Swenson, A. H. Kesarwala. NMR in
Biomedicine 2021, 34, e4588. https://
doi.org/10.1002/nbm.4588.
• Low-cost High-Pressure ClinicalScale 50% Parahydrogen Generator
Using Liquid Nitrogen at 77 K. B.
Chapman, B. Joalland, C. Meersman, J.
Ettedgui, R. E. Swenson, M. C. Krishna,
P. Nikolaou, K.V. Kovtunov, O. G.
Salnikov, I. V. Koptyug, M. E.
Gemeinhardt, B. M. Goodson, R. V.
Shchepin, and E. Y. Chekmenev. Anal.
Chem. 2021, 93, 8476–8483.
• Real Time Insight into In Vivo
Redox Status utilizing Hyperpolarized
[1-13C] N-Acetyl Cysteine. K.
Yamamoto, A. Opina, D. Sail, B.
Blackman, K. Saeito, J. R. Brender, R. M.
Malinowski, T. Seki, N. Oshima, D. R.
Crooks, S. Kishimoto, Y. Saida, Y.
Otowa, P. L. Choyke, J. H. ArdenkjaerLarsen, J. B. Mitchell, W. M. Linehan, R.
E. Swenson, M. C. Krishna. Sci. Reports
2021, 11, 12155.
Dated: May 23, 2024.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2024–11796 Filed 5–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
E:\FR\FM\30MYN1.SGM
30MYN1
Federal Register / Vol. 89, No. 105 / Thursday, May 30, 2024 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Aging and
Neurodegeneration Integrated Review Group;
Cellular and Molecular Biology of
Neurodegeneration Study Section.
Date: June 24–25, 2024.
Time: 8:30 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Darcy, 1515 Rhode Island Ave.
NW, Washington, DC 20005.
Meeting Format: In Person.
Contact Person: Laurent Taupenot, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4188,
MSC 7850, Bethesda, MD 20892, 301–435–
1203, laurent.taupenot@nih.gov.
Name of Committee: Infectious Diseases
and Immunology B Integrated Review Group;
Bacterial-Host Interactions Study Section.
Date: June 25–26, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Uma Basavanna, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 827–1398, uma.basavanna@
nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Neurodifferentiation,
Plasticity, Regeneration and Rhythmicity
Study Section.
Date: June 25–26, 2024.
Time: 9:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Jacek Topczewski, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002A1,
Bethesda, MD 20892, (301) 594–7574,
topczewskij2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Biobehavioral Processes.
Date: June 25–26, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
20:03 May 29, 2024
Jkt 262001
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Jeanne M. McCaffery,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–3854, jeanne.mccaffery@
nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Science of Implementation in Health and
Healthcare Study Section.
Date: June 25–26, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Wenjuan Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3154,
Bethesda, MD 20892, (301) 480–8667,
wangw22@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Health Services Research: Health Information
Technology and Clinical Informatics.
Date: June 25–26, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Debasmita Patra, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1006E,
Bethesda, MD 20892, (301) 827–5187,
debasmita.patra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Advancing
Therapeutics.
Date: June 25–26, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Lystranne Alysia Maynard
Smith, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–402–4809,
lystranne.maynard-smith@nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Population based Research in Infectious
Disease Study Section.
Date: June 25–26, 2024.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: In Person and Virtual
Meeting.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
46897
Contact Person: Lisa Steele, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 257–
2638, steeleln@csr.nih.gov.
Name of Committee: Infectious Diseases
and Immunology A Integrated Review Group;
Bacterial Virulence Study Section.
Date: June 25–26, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Susan Daum, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
Bethesda, MD 20892, 301–827–7233,
susan.boyle-vavra@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 23, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–11853 Filed 5–29–24; 8:45 am].
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; NCCIH Training and
Education Review Panel (CT).
Date: June 24, 2024
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\30MYN1.SGM
30MYN1
]]>Agencies
[Federal Register Volume 89, Number 105 (Thursday, May 30, 2024)]
[Notices]
[Pages 46896-46897]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11853]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
[[Page 46897]]
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Aging and Neurodegeneration Integrated Review
Group; Cellular and Molecular Biology of Neurodegeneration Study
Section.
Date: June 24-25, 2024.
Time: 8:30 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant applications.
Place: The Darcy, 1515 Rhode Island Ave. NW, Washington, DC
20005.
Meeting Format: In Person.
Contact Person: Laurent Taupenot, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4188, MSC 7850, Bethesda, MD
20892, 301-435-1203, [email protected].
Name of Committee: Infectious Diseases and Immunology B
Integrated Review Group; Bacterial-Host Interactions Study Section.
Date: June 25-26, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Uma Basavanna, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892, (301) 827-1398,
[email protected].
Name of Committee: Molecular, Cellular and Developmental
Neuroscience Integrated Review Group; Neurodifferentiation,
Plasticity, Regeneration and Rhythmicity Study Section.
Date: June 25-26, 2024.
Time: 9:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Jacek Topczewski, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002A1, Bethesda, MD 20892, (301)
594-7574, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Biobehavioral Processes.
Date: June 25-26, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Jeanne M. McCaffery, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-3854,
[email protected].
Name of Committee: Healthcare Delivery and Methodologies
Integrated Review Group; Science of Implementation in Health and
Healthcare Study Section.
Date: June 25-26, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Wenjuan Wang, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3154, Bethesda, MD 20892, (301) 480-8667,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics in Health Services Research: Health Information
Technology and Clinical Informatics.
Date: June 25-26, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Debasmita Patra, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1006E, Bethesda, MD 20892, (301)
827-5187, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Advancing Therapeutics.
Date: June 25-26, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Lystranne Alysia Maynard Smith, Ph.D.,
Scientific Review Officer, Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-
402-4809, [email protected].
Name of Committee: Population Sciences and Epidemiology
Integrated Review Group; Population based Research in Infectious
Disease Study Section.
Date: June 25-26, 2024.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: In Person and Virtual Meeting.
Contact Person: Lisa Steele, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, (301) 257-
2638, [email protected].
Name of Committee: Infectious Diseases and Immunology A
Integrated Review Group; Bacterial Virulence Study Section.
Date: June 25-26, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Susan Daum, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3202, Bethesda, MD 20892, 301-827-7233,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: May 23, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-11853 Filed 5-29-24; 8:45 am].
BILLING CODE 4140-01-P
